TP53 and osteosarcoma: In various cancer cell lines and primary tumors, e.g., osteosarcoma and melanoma, TRIB2 overexpression has been shown to mediate resistance against 5-FU through the disruption of AKT/FOXO and AKT/MDM2/p53 pathways [12].